ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of an Algorithm for Intensive s.c. Insulin Therapy in Emergency Room Patients With Hyperglycaemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00353431
Recruitment Status : Completed
First Posted : July 18, 2006
Results First Posted : May 8, 2012
Last Update Posted : May 18, 2012
Sponsor:
Information provided by (Responsible Party):
University Hospital, Basel, Switzerland

Brief Summary:
The aim of this study is to test the safety and efficacy of a new algorithm for intensive s.c. insulin injection in medical emergency patients with hyperglycaemia (plasma glucose concentration ≥ 8 mmol/l)

Condition or disease Intervention/treatment Phase
Hyperglycemias Drug: Novorapid ®, Novo Nordisk, Denmark Not Applicable

Detailed Description:

BACKGROUND: Prospective randomized trials have shown that near-normoglycemic blood glucose control using insulin infusions achieves a significant reduction in mortality of severely ill patients in intensive care units, of patients with acute myocardial infarction and with stroke. This implies that most severely ill patients with hyperglycemia should be treated with insulin to reach near-normoglycemia. However, this is not common practice today in emergency room admissions outside the intensive care unit, and strategies to achieve near-normoglycemia safely outside the ICU setting with s.c. injections (insulin infusions are too risky outside the ICU) have not been established.

AIM: To evaluate an insulin therapy algorithm using s.c. injections which permits effective and safe glycemic management of emergency room patients with hyperglycemia.

DESIGN: Randomized, controlled trial with an open intervention. Patients presenting with hyperglycemia on admission to the emergency room are randomized 1:1 either to conventional treatment (conventional insulin group) or to intensive treatment (intensive insulin group).

METHODS: 140 patients admitted to the medical emergency rooms of the University Hospital Basel and the Regional Hospital of Solothurn will be included and randomized as described above. All patients with plasma glucose levels exceeding 8.0 mmol/l will be included.

Exclusion criteria include severely immunocompromised patients, patients in shock, patients with terminal illnesses on palliative care, type 1 diabetes with or without ketoacidosis and patients which require intensive care unit (ICU) or cardial care unit (CCU) therapy.

PRIMARY ENDPOINT: Time in the glycaemic target range (5.5-7.0 mmol/l) during the period of observation of 48 hours (expected to be longer in the intensive insulin group)

SECONDARY ENDPOINTS: Time to reach the target range. Frequency of hypoglycaemia (plasma glucose < 3.8 mmol/l). Frequency of severe hypoglycaemia (plasma glucose < 2.5 mmol/l. Frequency of hypokalaemia.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 130 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of an Algorithm for Intensive s.c. Insulin Therapy in Emergency Room Patients With Hyperglycaemia
Study Start Date : December 2006
Actual Primary Completion Date : April 2010
Actual Study Completion Date : October 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hyperglycemia
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: 1

Conventional insulin group:

In the conventional insulin group only the meal-glucose adapted sliding scale at beginning is pre-determined. All adaptations of the insulin sliding scale remain upon the discretion of the treating physician.

Drug: Novorapid ®, Novo Nordisk, Denmark
Comparison of a sliding scale with an intensive s.c. scale
Other Names:
  • insulin aspart,
  • Novolog
Experimental: 2

Intensive insulin therapy algorithm:

The algorithm in the intensive insulin group contains four insulin resistance factors, depending on baseline features of the patients and on the changes of plasma glucose levels after insulin administration. Every two to four hours the plasma glucose level is measured and Insulin aspart (Novorapid®) is injected s.c. according to the scheme. If the patient is eating, the dose of Insulin aspart (NovoRapid®)is increased according to the amount of carbohydrate intake.

Drug: Novorapid ®, Novo Nordisk, Denmark
Comparison of a sliding scale with an intensive s.c. scale
Other Names:
  • insulin aspart,
  • Novolog



Primary Outcome Measures :
  1. Time in the Glycaemic Target Range (5.5-7.0 mmol/l) During the Period of Observation of 48 Hours [ Time Frame: 48 h ]
    Hours in which the plasma glucose was between 5.5 and 7.0 mmol/l (expected to be longer in the intensive insulin group)


Secondary Outcome Measures :
  1. Time to Reach the Target Range [ Time Frame: 24 h ]
    Hours needed to reach 5.5.-7.0 mmol/l (expected to be shorter in the intensive insulin group).

  2. Frequency of Hypoglycemia [ Time Frame: during observation of 48 hours ]
    absolute number of participants with hypoglycemia (plasma glucose < 3.8 mmol/l) (safety endpoint, expected to be similar in the two groups)

  3. Frequency of Severe Hypoglycaemia [ Time Frame: during observation of 48 hours ]
    Number of participants with severe hypoglycaemia (plasma glucose < 2.5 mmol/l) (safety endpoint, expected to be similar in the two groups)

  4. Frequency of Hypokalaemia [ Time Frame: during observation of 48 hours ]
    Number of participants with hypokalaemia (potassium < 3.6 mmol/l, safety endpoint, expected to be similar in the two groups)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • all patients with hyperglycaemia (≥ 8.0 mmol/l) admitted to the medical emergency room.
  • patients with presumed hospitalisation in ER or medical ward of more than 48 h duration.

Exclusion Criteria:

  • patients in shock (defined as hypotension or shock index > 1 with oliguria, changed mental status and metabolic acidosis)
  • patients with a terminal illness on palliative care
  • patients with type 1 diabetes
  • patients with insulin pump therapy
  • patients with need for hospitalisation in the intensive or coronary care unit.
  • patients with presumed hospitalisation shorter than 48 hours
  • known pregnancy (in women with childbearing potential pregnancy test for exclusion mandatory)
  • no informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00353431


Locations
Switzerland
Division of Endocrinology, Diabetes & Clinical Nutrition, Dept of Internal Medicine,
Basel, Baselstadt, Switzerland, 4031
Sponsors and Collaborators
University Hospital, Basel, Switzerland
Investigators
Principal Investigator: Ulrich Keller, MD, Prof Division of Endocrinology, Diabetes & Clinical Nutrition, Dept of Internal Medicine

Responsible Party: University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier: NCT00353431     History of Changes
Other Study ID Numbers: EKBB13/06
ISRCTN55224894 ( Registry Identifier: Current Controlled Trials Database )
First Posted: July 18, 2006    Key Record Dates
Results First Posted: May 8, 2012
Last Update Posted: May 18, 2012
Last Verified: May 2012

Keywords provided by University Hospital, Basel, Switzerland:
Hyperglycaemia
algorithm
emergency
s.c. insulin therapy
Emergency patient

Additional relevant MeSH terms:
Emergencies
Hyperglycemia
Disease Attributes
Pathologic Processes
Glucose Metabolism Disorders
Metabolic Diseases
Insulin, Globin Zinc
Insulin
Insulin Aspart
Hypoglycemic Agents
Physiological Effects of Drugs